A Phase I/IIa, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-8263 in Adult Patients With Advanced Malignant Tumors
Latest Information Update: 16 Sep 2024
At a glance
- Drugs JAB-8263 (Primary)
- Indications Acute myeloid leukaemia; Haematological malignancies; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Jacobio Pharmaceuticals
- 22 Mar 2023 According to Jacobio media release, the phase I dose escalation portion in solid tumors and hematological malignancies is ongoing the USA and China simultaneously. RP2D is expected to be determined in the Q2 of 2023.
- 09 Mar 2023 Planned End Date changed from 1 Sep 2023 to 1 Sep 2024.
- 09 Mar 2023 Planned primary completion date changed from 1 Jan 2023 to 1 Jan 2024.